Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Next leg $.064 $HEMP
$INSY pop coming
$CIIX nice support here
MOMO Breakout Bids are stacking $HEMP .0365 x1,280,300
Bids are stacking $HEMP .0365 x1,280,300
loading zone $HEMP may close green today
loading zone $HEMP may close green today
Hemp, Inc. $HEMP & Creation of Proprietary Industrial Hemp Strains as U.S. Senate Supports Cannabis Seed Bank
https://www.gurufocus.com/news/689417/hemp-inc-announces-creation-of-proprietary-industrial-hemp-strains-as-us-senate-supports-cannabis-seed-bank
Hemp, Inc. $HEMP & Creation of Proprietary Industrial Hemp Strains as U.S. Senate Supports Cannabis Seed Bank
https://www.gurufocus.com/news/689417/hemp-inc-announces-creation-of-proprietary-industrial-hemp-strains-as-us-senate-supports-cannabis-seed-bank
$HEMP Massive $867 Billion Farm Bill Pushes Hemp Legalization Near the Finish Line, Hemp, Inc. $HEMP Reports https://globenewswire.com/news-release/2018/12/12/1666054/0/en/Massive-867-Billion-Farm-Bill-Pushes-Hemp-Legalization-Near-the-Finish-Line-Hemp-Inc-Reports.html
Massive $867 Billion Farm Bill Pushes Hemp Legalization Near the Finish Line, Hemp, Inc. $HEMP Reports https://globenewswire.com/news-release/2018/12/12/1666054/0/en/Massive-867-Billion-Farm-Bill-Pushes-Hemp-Legalization-Near-the-Finish-Line-Hemp-Inc-Reports.html
$HEMP Legalization of Hemp Passes Senate and House, Hemp, Inc. $HEMP
https://globenewswire.com/news-release/2018/12/14/1667364/0/en/Legalization-of-Hemp-Passes-Senate-and-House-Hemp-Inc-Announces.html
$HEMP Legalization of Hemp Passes Senate and House, Hemp, Inc. $HEMP
https://globenewswire.com/news-release/2018/12/14/1667364/0/en/Legalization-of-Hemp-Passes-Senate-and-House-Hemp-Inc-Announces.html
$CLDC China Lending Launch Of New Supply Chain Financing Services Including Business Factoring Program https://www.prnewswire.com/news-releases/china-lending-corporation-launches-new-supply-chain-financing-services-300761841.html
$CLDC China Lending Launch Of New Supply Chain Financing Services Including Business Factoring Program https://www.prnewswire.com/news-releases/china-lending-corporation-launches-new-supply-chain-financing-services-300761841.html
Big news CBD stock $INSY “Our strategic shift in focus away from opioids and to pharmaceutical-grade cannabinoids and novel drug delivery systems continues to gain momentum and has been driven by our strong commitment to advancing our diverse product pipeline,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics. “Through this intense focus on our reprioritized pipeline over the last year, which has been anchored by a patient-centric mission and commitment, we are radically transforming this company. As we look forward, we have the potential to submit six new drug applications over the next three years, two of which are scheduled for 2019.”
Big news CBD stock $INSY “Our strategic shift in focus away from opioids and to pharmaceutical-grade cannabinoids and novel drug delivery systems continues to gain momentum and has been driven by our strong commitment to advancing our diverse product pipeline,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics. “Through this intense focus on our reprioritized pipeline over the last year, which has been anchored by a patient-centric mission and commitment, we are radically transforming this company. As we look forward, we have the potential to submit six new drug applications over the next three years, two of which are scheduled for 2019.”
Doubling Down. $HEMP .10+ coming imo.
Doubling Down. $HEMP .10+ coming imo.
$INSY INSYS Therapeutics Says 9 Companies Have Signed NDAs Related to the Potential Sale of its Opioid Business, Says Will Provide an Update with Q1 Results https://www.wsj.com/articles/insys-looks-to-sell-opioid-related-assets-including-subsys-1541482212
$CIIX CBD Infused Hemp Wine. CIIX plans to launch CBD Hemp Wine, its private brand, hemp-infused, rice wine, through its wholly-owned foreign enterprise CBD Biotechnology Co. Ltd ("CBD Biotech"). Given the popularity of infused wine and liquor in recent years, CBD Biotech's new hemp-infused, rice wine was developed with the hemp enthusiast in mind. Moreover, CBD Biotech believes that there are potential long-term, functional benefits of hemp and rice wine.
https://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=291609
$CIIX CBD Infused Hemp Wine. CIIX plans to launch CBD Hemp Wine, its private brand, hemp-infused, rice wine, through its wholly-owned foreign enterprise CBD Biotechnology Co. Ltd ("CBD Biotech"). Given the popularity of infused wine and liquor in recent years, CBD Biotech's new hemp-infused, rice wine was developed with the hemp enthusiast in mind. Moreover, CBD Biotech believes that there are potential long-term, functional benefits of hemp and rice wine.
https://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=291609
CBD_HEMP $CIIX .555 -0.025 (-4.31%) Oversold Look at 3 month chart
CBD_HEMP $CIIX .555 -0.025 (-4.31%) Oversold Look at 3 month chart
$HEMP Hemp, Inc. Provides CBS Behind-The-Scenes Access to the Largest Hemp Processing Mill in the Western Hemisphere https://globenewswire.com/news-release/2018/04/09/1466793/0/en/Hemp-Inc-Provides-CBS-Behind-The-Scenes-Access-to-the-Largest-Hemp-Processing-Mill-in-the-Western-Hemisphere.html
$HEMP Hemp, Inc. Provides CBS Behind-The-Scenes Access to the Largest Hemp Processing Mill in the Western Hemisphere https://globenewswire.com/news-release/2018/04/09/1466793/0/en/Hemp-Inc-Provides-CBS-Behind-The-Scenes-Access-to-the-Largest-Hemp-Processing-Mill-in-the-Western-Hemisphere.html
$HEMP was $1.83 pps in 2014
$CLDC 1.10 +0.03 (2.80%
$CLDC 1.10 +0.03 (2.80%
$CIIX .56
Cannabis CBD Spray $INSY 5.12 +0.21 (4.28%)
Cannabis CBD Spray $INSY 5.12 +0.21 (4.28%)
$INSY Cannabidiol
All three trials with CBD oral solution are enrolling patients, including a Phase 2 study of childhood absence epilepsy, a Phase 3 study of infantile spasms, and a Phase 2 study of Prader-Willi syndrome.
The company expects to show initial results from the Phase 2 trial in childhood absence epilepsy late in the first quarter 2019 as the company continues to enroll patients.
Results of the long-term safety study of CBD in refractory pediatric epilepsy were reported on Dec. 3 at the American Epilepsy Society 2018 annual meeting and showed that the company’s proprietary formulation of the drug was generally well-tolerated, even at high doses, through 48 weeks of follow up.
The company is continuing to enroll patients in a Phase 2 study of Prader-Willi Syndrome across seven clinical sites with a plan to add additional sites in 2019. The company expects full results of this study in the second half of 2019.
Enrollment in the company’s Phase 3 study of infantile spasms has occurred at a slower pace than anticipated, and the company will provide an update once it has better visibility into enrollment.
Additionally, the company is committed to supporting three studies planned by the University of California San Diego School of Medicine’s Center for Medicinal Cannabis Research (CMCR) for initiation in 2019. The investigational new drug (IND) for CMCR’s autism study has been opened, and the INDs for the studies of early psychosis and anxiety in anorexia nervosa are expected to be opened in the first half of 2019—in the first and second quarters, respectively. Meanwhile, the company’s support for a study of CBD in cocaine dependence continues at the University of Montreal.
Lastly, alternative oral-dose formulations of CBD are in early development. With results from nonclinical studies expected in the first quarter, the next phase of development, including clinical trials targeting additional chronic indications, is scheduled to commence in the latter part of 2019.
$INSY Cannabidiol
All three trials with CBD oral solution are enrolling patients, including a Phase 2 study of childhood absence epilepsy, a Phase 3 study of infantile spasms, and a Phase 2 study of Prader-Willi syndrome.
The company expects to show initial results from the Phase 2 trial in childhood absence epilepsy late in the first quarter 2019 as the company continues to enroll patients.
Results of the long-term safety study of CBD in refractory pediatric epilepsy were reported on Dec. 3 at the American Epilepsy Society 2018 annual meeting and showed that the company’s proprietary formulation of the drug was generally well-tolerated, even at high doses, through 48 weeks of follow up.
The company is continuing to enroll patients in a Phase 2 study of Prader-Willi Syndrome across seven clinical sites with a plan to add additional sites in 2019. The company expects full results of this study in the second half of 2019.
Enrollment in the company’s Phase 3 study of infantile spasms has occurred at a slower pace than anticipated, and the company will provide an update once it has better visibility into enrollment.
Additionally, the company is committed to supporting three studies planned by the University of California San Diego School of Medicine’s Center for Medicinal Cannabis Research (CMCR) for initiation in 2019. The investigational new drug (IND) for CMCR’s autism study has been opened, and the INDs for the studies of early psychosis and anxiety in anorexia nervosa are expected to be opened in the first half of 2019—in the first and second quarters, respectively. Meanwhile, the company’s support for a study of CBD in cocaine dependence continues at the University of Montreal.
Lastly, alternative oral-dose formulations of CBD are in early development. With results from nonclinical studies expected in the first quarter, the next phase of development, including clinical trials targeting additional chronic indications, is scheduled to commence in the latter part of 2019.
$INSY Epinephrine
As a needle-free delivery method, INSYS’ epinephrine nasal spray represents a potential alternative to intramuscular injection. As reported in June 2018, the proof-of-concept study for the company’s epinephrine nasal spray product candidate showed that the drug as formulated was readily absorbed through the nasal mucosa. Subsequently, the FDA granted Fast Track designation for this investigational product in August of 2018 and provided specific guidance for clinical development and filing requirements at the end-of-Phase 2 meeting in August.
Given clinical and regulatory progress to date, INSYS believes the epinephrine NDA remains on track for filing during the fourth quarter of 2019, pending successful completion of a confirmatory PK study and no additional clinical studies requested by the FDA. The confirmatory PK study will follow completion of the now fully enrolled 48-patient dose-finding study that is expected to report results in March. Considering the Fast Track designation, INSYS plans to meet again with the FDA early in the second quarter to confirm the design of the subsequent clinical development program.
Also of note, data from the product candidate’s clinical development program will be presented at the American Academy of Allergy, Asthma and Immunology 2019 annual meeting in late February 2019. The abstract, titled “A Phase 1, Single-Dose, Open-Label, 5-Treatment, Crossover, Pharmacokinetic Study of Comparative Bioavailability of Epinephrine Nasal Spray and EpiPen® in Healthy Adults with Seasonal Allergies,” has been accepted as a poster presentation.
$INSY Epinephrine
As a needle-free delivery method, INSYS’ epinephrine nasal spray represents a potential alternative to intramuscular injection. As reported in June 2018, the proof-of-concept study for the company’s epinephrine nasal spray product candidate showed that the drug as formulated was readily absorbed through the nasal mucosa. Subsequently, the FDA granted Fast Track designation for this investigational product in August of 2018 and provided specific guidance for clinical development and filing requirements at the end-of-Phase 2 meeting in August.
Given clinical and regulatory progress to date, INSYS believes the epinephrine NDA remains on track for filing during the fourth quarter of 2019, pending successful completion of a confirmatory PK study and no additional clinical studies requested by the FDA. The confirmatory PK study will follow completion of the now fully enrolled 48-patient dose-finding study that is expected to report results in March. Considering the Fast Track designation, INSYS plans to meet again with the FDA early in the second quarter to confirm the design of the subsequent clinical development program.
Also of note, data from the product candidate’s clinical development program will be presented at the American Academy of Allergy, Asthma and Immunology 2019 annual meeting in late February 2019. The abstract, titled “A Phase 1, Single-Dose, Open-Label, 5-Treatment, Crossover, Pharmacokinetic Study of Comparative Bioavailability of Epinephrine Nasal Spray and EpiPen® in Healthy Adults with Seasonal Allergies,” has been accepted as a poster presentation.
$INSY Naloxone
Results of a pharmacokinetic (PK) study reported in early November showed a distinctive profile for the company’s naloxone nasal spray product candidate in comparison to the current standards, including intramuscular (IM) injection. INSYS believes that the characteristics of its drug hold particular relevance in the context of rising rates of overdose from highly potent synthetic opioids, as standard doses of currently approved naloxone products may not be sufficient due to the drug’s relatively short half-life.
INSYS is currently completing a required nonclinical juvenile toxicity study related to naloxone, which has been fully enrolled, and expects the results of that program in early March of 2019. Pending positive results from that study, the current target timeframe for NDA submission remains around the end of the first quarter of 2019.
$INSY Naloxone
Results of a pharmacokinetic (PK) study reported in early November showed a distinctive profile for the company’s naloxone nasal spray product candidate in comparison to the current standards, including intramuscular (IM) injection. INSYS believes that the characteristics of its drug hold particular relevance in the context of rising rates of overdose from highly potent synthetic opioids, as standard doses of currently approved naloxone products may not be sufficient due to the drug’s relatively short half-life.
INSYS is currently completing a required nonclinical juvenile toxicity study related to naloxone, which has been fully enrolled, and expects the results of that program in early March of 2019. Pending positive results from that study, the current target timeframe for NDA submission remains around the end of the first quarter of 2019.